Cargando…

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report

INTRODUCTION: Despite initial benefit, virtually all patients suffering from EGFR-mutant NSCLC experience acquired resistance to tyrosine kinase inhibitors (TKIs), driven by multiple mechanisms. Recent reports have identified oncogenic kinase fusions as off-target resistance mechanisms; however, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Enrico, Diego, Lacroix, Ludovic, Chen, Jeanne, Rouleau, Etienne, Scoazec, Jean-Yves, Loriot, Yohann, Tselikas, Lambros, Jovelet, Cécile, Planchard, David, Gazzah, Anas, Mezquita, Laura, Ngo-Camus, Maud, Michiels, Stefan, Massard, Christophe, Recondo, Gonzalo, Facchinetti, Francesco, Remon, Jordi, Soria, Jean-Charles, André, Fabrice, Vassal, Gilles, Friboulet, Luc, Besse, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474286/ https://www.ncbi.nlm.nih.gov/pubmed/34589930 http://dx.doi.org/10.1016/j.jtocrr.2020.100023

Ejemplares similares

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
por: Recondo, Gonzalo, et al.
Publicado: (2020)

Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non–Small-Cell Lung Cancer
por: Remon, Jordi, et al.
Publicado: (2019)

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer
por: Geraud, Arthur, et al.
Publicado: (2020)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer
por: Jovelet, Cécile, et al.
Publicado: (2017)

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay
por: Remon, Jordi, et al.
Publicado: (2020)

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers
por: Cabel, Luc, et al.
Publicado: (2018)

Correction: EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR
por: Madic, Jordan, et al.
Publicado: (2019)

Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test
por: Vasseur, Damien, et al.
Publicado: (2022)

Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
por: Gazzah, Anas, et al.
Publicado: (2013)

Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients
por: Koeppel, Florence, et al.
Publicado: (2017)

Method for semi-automated microscopy of filtration-enriched circulating tumor cells
por: Pailler, Emma, et al.
Publicado: (2016)

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
por: Fizazi, Karim, et al.
Publicado: (2015)

Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic
por: Bayle, Arnaud, et al.
Publicado: (2021)

Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma
por: Danlos, François-Xavier, et al.
Publicado: (2023)

EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR
por: Madic, Jordan, et al.
Publicado: (2018)

The efficacy of immune checkpoint inhibitors in thoracic malignancies
por: Remon, Jordi, et al.
Publicado: (2021)

Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
por: Remon, Jordi, et al.
Publicado: (2017)

Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
por: Remon, Jordi, et al.
Publicado: (2017)

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
por: Facchinetti, Francesco, et al.
Publicado: (2019)

Cystic brain metastases and RET fusion in lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours
por: Bahleda, Rastislav, et al.
Publicado: (2015)

CD103(+)CD8(+) T(RM) Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17
por: Corgnac, Stéphanie, et al.
Publicado: (2020)

Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer
por: Pradat, Yoann, et al.
Publicado: (2023)

Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score
por: Pierro, Monica, et al.
Publicado: (2022)

Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
por: Bayle, Arnaud, et al.
Publicado: (2023)

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
por: Remon, Jordi, et al.
Publicado: (2020)

Pain after Interventional Radiology in Oncology: A Case-Control Study from a 5-Year Cohort
por: Ayaden, Narimane, et al.
Publicado: (2022)

Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study
por: Virginia, Bluthgen Maria, et al.
Publicado: (2017)

1617P Sustained cancer clinical trial activity during the COVID-19 pandemic
por: Bayle, A., et al.
Publicado: (2021)

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
por: De Giglio, Andrea, et al.
Publicado: (2020)

Targeting genome integrity dysfunctions impedes metastatic potency in non–small cell lung cancer circulating tumor cell–derived explants
por: Tayoun, Tala, et al.
Publicado: (2022)

Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib
por: Facchinetti, Francesco, et al.
Publicado: (2021)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
por: Mezquita, Laura, et al.
Publicado: (2018)

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients
por: Boros, Angela, et al.
Publicado: (2017)

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
por: Cabel, Luc, et al.
Publicado: (2017)

Twitter as a Medical Media Among French Young Oncologists: Results from a National Survey
por: Roulleaux Dugage, Matthieu, et al.
Publicado: (2021)

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer
por: Pailler, E., et al.
Publicado: (2015)

Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?
por: Martin-Romano, Patricia, et al.
Publicado: (2021)

Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer
por: Lindsay, C. R., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_74mbtoniua0t8s2nscnst7kgho